Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dell Technologies Inc (DELL) vs Nuvalent Inc (NUVL) Price & Performance

Dell Technologies IncTrade
Nuvalent IncTrade

Price performance (Past 24H)

Key statistics

Dell Technologies Inc vs Nuvalent Inc — how do they compare? Dell Technologies Inc trades at $409.9 (market cap $295.64B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Dell Technologies Inc is far larger — about 30.1× Nuvalent Inc's market cap, and Dell Technologies Inc pays a 0.55% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.

DELLNUVL
Market Cap
$295.64B$9.81B
Sector
TechnologyTechnology
52-Week High
$466.02$123.96
52-Week Low
$111.10$72.16
Enterprise Value
$315.22B$8.52B
Dividend Yield
0.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dell Technologies Inc

Dell Technologies (DELL) trades at $426.9, down 1.87% on the day, but remains in a bullish technical trend with strong fundamental momentum. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $4.86 significantly exceeding the $2.96 forecast. Revenue for 2025 reached $95.57 billion, with a net income margin improving to 4.8%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $487.06, suggesting substantial upside from current levels.

The outlook for DELL is favorable, driven by its position in AI infrastructure and partnerships with leaders like Nvidia. Key opportunities include projected revenue growth to $134 billion in 2026 and expanding profitability. Risks involve competitive pressures in the PC market, memory chip supply constraints, and macroeconomic sensitivity. The stock presents a compelling growth story, but investors should weigh execution risks against the strong analyst conviction.

Nuvalent Inc

Nuvalent (NUVL) trades at $123.94, showing minimal daily movement with a 0.03% gain. The stock is in focus following GSK's proposed acquisition at $124 per share, announced June 2026. Technically, the price is at the acquisition offer level with a bullish moving average signal but overbought RSI readings. Fundamentally, the company reports significant losses with negative ROE and ROA, while cash flow remains supported by financing activities.

The investment outlook is dominated by the pending acquisition, limiting upside beyond the offer price. Key risks include deal completion uncertainty and ongoing operational losses. Analyst sentiment is mixed with a slight hold bias, reflecting caution until transaction closure. Shareholder value hinges on successful deal execution amid financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dell Technologies Inc

VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses

Read more on DELL

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

Read more on NUVL